Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $1,700,000 Small Business Innovation Research (SBIR) grant to advance Zylö’s proprietary nitric-oxide-releasing topical drug candidate into clinical trials. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into a broad-ranging agreement with Amifar Laboratorios Spain to supply Z-pods to further enhance Amifar’s new line of advanced cosmetics. Amifar and Zylö have initiated a product development collaboration beginning with two actives and have plans to expand the list of actives over time. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that Charles E. Hinkle joined its executive team as chief financial officer during the first quarter. Charles began his career as a management consultant at Bain & Company and Bain Capital. Read more >>
Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a Joint Venture with Zylo Therapeutics. This Joint Venture will utilize Zylo’s innovative sustained release topical delivery system that was originally developed at Albert Einstein College of Medicine using Silo Pharma’s expertise in the use of psychedelics. Read more >>
Hoth has a partnership agreement with Zylö Therapeutics Inc., to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Read more >>
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced Jay Blankenship M.D. has joined its executive team as vice president of business development. Read more >>
Grapefruit USA, Inc., a fully licensed California based cannabis company, is announcing today that it has commenced production of the Hourglass™ time release THC+CBD delivery cream at its manufacturing facility in the Coachillin Canna-Business Park in Desert Hot Springs, California, pursuant to its Exclusive License and Supply Agreement with Zylö Therapeutics Inc. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into an exclusive agreement with Grapefruit USA, Inc. to supply its Z-pod™ system as the technological underpinning of Grapefruit’s Hourglass™ time-release cannabinoid topical cream. Read more >>
Developed in partnership with Zylö Therapeutics, Hoth’s AEA-loaded Z-pods™ are currently being tested for approval in the treatment of Cutaneous Lupus Erythematosus (CLE). Read more >>
